Table 2.
Tumour characteristics of study subjects by quartiles of serum angiotensin-converting enzyme 2 (ACE2) levels on postoperative day 1.
| Serum ACE2 levels (ng/mL) |
p | ||||
|---|---|---|---|---|---|
| ≤3.21 (n = 80) |
3.22-3.86 (n = 80) |
3.87-4.42 (n = 80) |
≥4.43 (n = 80) |
||
| Histology n(%) | |||||
| Adenocarcinoma | 72 (90.0) | 73 (91.3) | 74 (92.5) | 68 (85.0) | 0.93 |
| Squamous cell carcinoma | 3 (3.8) | 2 (2.5) | 2 (2.5) | 4 (5.0) | |
| Adenosquamous cell carcinoma | 1 (1.2) | 1 (1.2) | 0 (0) | 1 (1.2) | |
| Neuroendocrine carcinoma | 4 (5.0) | 4 (5.0) | 4 (5.0) | 7 (8.8) | |
| Clinical stages n(%) | |||||
| IA | 25 (31.3) | 23 (28.8) | 22 (27.5) | 21 (26.3) | 1.00 |
| IB | 28 (35.0) | 27 (33.8) | 27 (33.8) | 25 (31.3) | |
| IIA | 10 (12.5) | 12 (15.0) | 12 (15.0) | 13 (16.2) | |
| IIB | 4 (5.0) | 4 (5.0) | 5 (6.2) | 6 (7.5) | |
| IIIA | 12 (15.0) | 13 (16.2) | 12 (15.0) | 13 (16.2) | |
| IIIB | 1 (1.2) | 1 (1.2) | 2 (2.5) | 2 (2.5) | |